Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib monotherapy as third-line therapy in progressed ovarian epithelial or primary peritoneal cancer
2008-002156-14Phase 2Terminated
- Sponsor
- Foundation of Experimental and Clinical Oncology
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC), sponsored by Foundation of Experimental and Clinical Oncology. Primary endpoint: Progression-free survival (PFS). Started Jul 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-002156-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002156-14.